RU2698911C2 - Композиции, содержащие антитела к cd38 и леналидомид - Google Patents

Композиции, содержащие антитела к cd38 и леналидомид Download PDF

Info

Publication number
RU2698911C2
RU2698911C2 RU2015127089A RU2015127089A RU2698911C2 RU 2698911 C2 RU2698911 C2 RU 2698911C2 RU 2015127089 A RU2015127089 A RU 2015127089A RU 2015127089 A RU2015127089 A RU 2015127089A RU 2698911 C2 RU2698911 C2 RU 2698911C2
Authority
RU
Russia
Prior art keywords
lenalidomide
antibody
compound
antibodies
seq
Prior art date
Application number
RU2015127089A
Other languages
English (en)
Russian (ru)
Other versions
RU2015127089A (ru
Inventor
Байрон К. ХАНН
III Томас Г. МАРТИН
Блейк Т. АФТАБ
Блейк Томкинсон
Original Assignee
Санофи
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи, Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния filed Critical Санофи
Publication of RU2015127089A publication Critical patent/RU2015127089A/ru
Application granted granted Critical
Publication of RU2698911C2 publication Critical patent/RU2698911C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2015127089A 2012-12-07 2013-12-06 Композиции, содержащие антитела к cd38 и леналидомид RU2698911C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261734524P 2012-12-07 2012-12-07
US61/734,524 2012-12-07
US201361769247P 2013-02-26 2013-02-26
US61/769,247 2013-02-26
US201361808372P 2013-04-04 2013-04-04
US61/808,372 2013-04-04
PCT/US2013/073540 WO2014089416A1 (en) 2012-12-07 2013-12-06 Compositions comprising anti-cd38 antibodies and lenalidomide

Publications (2)

Publication Number Publication Date
RU2015127089A RU2015127089A (ru) 2017-01-13
RU2698911C2 true RU2698911C2 (ru) 2019-09-02

Family

ID=50884019

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015127089A RU2698911C2 (ru) 2012-12-07 2013-12-06 Композиции, содержащие антитела к cd38 и леналидомид

Country Status (31)

Country Link
EP (2) EP3597191A1 (enExample)
JP (2) JP6499971B2 (enExample)
KR (2) KR102193045B1 (enExample)
CN (1) CN105263520B (enExample)
AR (1) AR093844A1 (enExample)
AU (2) AU2013355064B2 (enExample)
BR (1) BR112015012987A2 (enExample)
CA (1) CA2893946A1 (enExample)
CL (2) CL2015001558A1 (enExample)
CY (2) CY1122478T1 (enExample)
DK (1) DK2928495T3 (enExample)
ES (1) ES2731548T3 (enExample)
HR (1) HRP20191034T1 (enExample)
HU (3) HUE044142T2 (enExample)
IL (2) IL239234B (enExample)
LT (2) LT2928495T (enExample)
LU (1) LUC00187I2 (enExample)
MX (2) MX366296B (enExample)
MY (1) MY191601A (enExample)
NL (1) NL301079I2 (enExample)
NZ (1) NZ709215A (enExample)
PH (1) PH12015501263A1 (enExample)
PL (1) PL2928495T3 (enExample)
PT (1) PT2928495T (enExample)
RS (1) RS58829B1 (enExample)
RU (1) RU2698911C2 (enExample)
SG (3) SG11201504315WA (enExample)
SI (1) SI2928495T1 (enExample)
TW (2) TW201919699A (enExample)
UA (1) UA118255C2 (enExample)
WO (1) WO2014089416A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
WO2015195555A1 (en) * 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
JP6802791B2 (ja) 2014-12-04 2020-12-23 ヤンセン バイオテツク，インコーポレーテツド 急性骨髄性白血病の治療のための抗ｃｄ３８抗体
EP4553157A3 (en) 2015-05-20 2025-07-23 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
UA125115C2 (uk) 2015-06-22 2022-01-12 Янссен Байотек, Інк. Спосіб лікування суб'єкта, який має множинну мієлому (мм)
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下製剤及びその使用
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
JP7316930B2 (ja) 2016-07-15 2023-07-28 武田薬品工業株式会社 形質芽細胞及び形質細胞枯渇療法に対する応答を評価するための方法及び材料
JP2021502961A (ja) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法
CN112739715A (zh) 2018-01-12 2021-04-30 武田药品工业株式会社 抗cd38抗体的皮下给药
KR102286500B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
KR102286499B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 약제학적 조성물
WO2019199135A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
JP7581052B2 (ja) * 2018-04-13 2024-11-12 サムヤン ホールディングス コーポレイション レナリドミドの経口用コーティング錠剤組成物
JP2021518424A (ja) * 2018-04-13 2021-08-02 サムヤン バイオファーマシューティカルズ コーポレイションＳａｍｙａｎｇ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ 様々な用量のレナリドミドの経口用錠剤組成物
KR20220080044A (ko) 2018-05-16 2022-06-14 얀센 바이오테크 인코포레이티드 암 요법에 사용하기 위한 bcma/cd3 및 gprdc5d/cd3 이중특이성 항체
IL281845B2 (en) * 2018-10-01 2025-06-01 Celgene Corp Combination therapy comprising 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and daratumumab for the treatment multiple myeloma
KR20220002891A (ko) * 2019-03-15 2022-01-07 모르포시스 아게 자가항체-매개 자가면역 질병의 치료를 위한 항-cd38 항체 및 이의 약제학적 조성물
CN113993543B (zh) * 2019-06-10 2024-07-12 武田药品工业株式会社 使用抗cd38抗体的组合疗法
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
IL292181A (en) * 2019-10-31 2022-06-01 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
KR20220159947A (ko) 2019-12-05 2022-12-05 사노피-아벤티스 유.에스. 엘엘씨 피하 투여를 위한 항-cd38 항체의 제형
US20250277051A1 (en) * 2021-08-02 2025-09-04 Hangzhou Unogen Biotech, Ltd Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148449A1 (en) * 2005-03-23 2009-06-11 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
US20100092489A1 (en) * 2006-09-26 2010-04-15 Genmab A/S Combination treatment of cd38-expressing tumors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
WO1998046645A2 (en) 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO2006068185A1 (ja) * 2004-12-21 2006-06-29 Nippon Kayaku Kabushki Kaisha エポキシ樹脂、エポキシ樹脂組成物及びその硬化物
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191840A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
PT2621531T (pt) * 2010-09-27 2017-03-13 Morphosys Ag Anticorpo anti-cd38 e lenalidomida ou bortezomibe para o tratamento de mieloma múltiplo e linfoma não-hodgkins
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148449A1 (en) * 2005-03-23 2009-06-11 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
US20100092489A1 (en) * 2006-09-26 2010-04-15 Genmab A/S Combination treatment of cd38-expressing tumors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KLEIN U. et al., Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone, Ann Hematol. 2009 Jan; 88(1):67-71. doi: 10.1007/s00277-008-0561-1. Epub 2008 Jul 31 - . *
VAN DER VEER M. S. et al., Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab, Haematologica. 2011 Feb; 96(2):284-90. doi: 10.3324/haematol.2010.030759. Epub 2010 Nov 25. *
VAN DER VEER M. S. et al., Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab, Haematologica. 2011 Feb; 96(2):284-90. doi: 10.3324/haematol.2010.030759. Epub 2010 Nov 25. KLEIN U. et al., Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone, Ann Hematol. 2009 Jan; 88(1):67-71. doi: 10.1007/s00277-008-0561-1. Epub 2008 Jul 31 - реферат. *

Also Published As

Publication number Publication date
EP2928495B1 (en) 2019-03-27
AU2013355064B2 (en) 2018-05-24
EP2928495A4 (en) 2016-05-11
HUE044142T2 (hu) 2019-09-30
TWI670062B (zh) 2019-09-01
IL239234A0 (en) 2015-07-30
CL2018003292A1 (es) 2019-02-01
HK1215536A1 (en) 2016-09-02
IL282542A (en) 2021-06-30
LUC00187I2 (enExample) 2024-07-01
MY191601A (en) 2022-07-01
CY1122478T1 (el) 2021-01-27
HRP20191034T1 (hr) 2019-08-23
SI2928495T1 (sl) 2019-07-31
UA118255C2 (uk) 2018-12-26
BR112015012987A2 (pt) 2017-09-12
TW201919699A (zh) 2019-06-01
EP3597191A1 (en) 2020-01-22
KR102193045B1 (ko) 2020-12-18
DK2928495T3 (da) 2019-06-24
PH12015501263A1 (en) 2015-08-17
AU2018211258A1 (en) 2018-08-16
CN105263520A (zh) 2016-01-20
MX2019008065A (es) 2019-09-23
AR093844A1 (es) 2015-06-24
HUS2000051I1 (hu) 2020-12-28
KR20200143503A (ko) 2020-12-23
PT2928495T (pt) 2019-07-04
RS58829B1 (sr) 2019-07-31
CY2020040I1 (el) 2021-03-12
LTC2928495I2 (lt) 2024-11-25
LT2928495T (lt) 2019-07-10
PL2928495T3 (pl) 2019-09-30
CY2020040I2 (el) 2021-05-05
JP6499971B2 (ja) 2019-04-10
ES2731548T3 (es) 2019-11-15
CA2893946A1 (en) 2014-06-12
SG10201704536PA (en) 2017-07-28
EP2928495A1 (en) 2015-10-14
CN105263520B (zh) 2020-03-13
LTPA2020537I1 (lt) 2020-12-28
HUS2000050I1 (hu) 2020-12-28
NZ709215A (en) 2020-08-28
MX2015007189A (es) 2016-03-21
AU2013355064A1 (en) 2015-07-09
SG10201913783PA (en) 2020-03-30
JP2019070020A (ja) 2019-05-09
RU2015127089A (ru) 2017-01-13
IL239234B (en) 2021-05-31
CL2015001558A1 (es) 2015-10-02
MX366296B (es) 2019-07-04
SG11201504315WA (en) 2015-07-30
JP2016506388A (ja) 2016-03-03
NL301079I2 (nl) 2021-03-29
TW201427663A (zh) 2014-07-16
WO2014089416A1 (en) 2014-06-12
KR20150091165A (ko) 2015-08-07

Similar Documents

Publication Publication Date Title
RU2698911C2 (ru) Композиции, содержащие антитела к cd38 и леналидомид
US10342869B2 (en) Compositions comprising anti-CD38 antibodies and lenalidomide
RU2670127C2 (ru) Композиции, включающие антитела к cd38 и карфилзомиб
HK1215536B (en) Compositions comprising anti-cd38 antibodies and lenalidomide
HK1219897B (en) Compositions comprising anti-cd38 antibodies and carfilzomib